Finally, the REACH-2 phase 3 trial evaluated ramucirumab, an anti-VEGFR-2 monoclonal antibody in patients with advanced HCC pre-treated with sorafenib and with a high alpha-fetoprotein (AFP) level (≥ 400 ng/mL) [35]. This evidence concerns the gene KDR and hepatocellular carcinoma.